🔗 Share this article

An underground market for unapproved slimming medications is being driven by social media fitness personalities and vendors on messaging platforms, according to recent findings.

Experimental Treatment Gaining Popularity Via Social Media

The experimental drug, which remains in research studies, is being advertised by social media influencers for its supposed weight-reducing properties. Viewers are urged to contact these accounts privately for source information, while also obtaining discount codes.

Active Commerce on Messaging Platforms

Separately, a robust trade exists on messaging services, where groups with thousands of members share comparison photos, injection guides and assertions of next-day British shipping. Vendors market the substance there before redirecting customers to WhatsApp for transactions.

Learning About The Experimental Drug

This medication is an investigational injection developed by US drugmaker Eli Lilly. The treatment affects three gut hormones – GLP-1, glucose-dependent insulinotropic polypeptide and glucagon. Preliminary studies suggest it could assist patients lose up to a quarter of their total weight. Nicknamed the “triple G”, the drug is being promoted online as the successor to Ozempic.

Healthcare Experts Express Worries

However, physicians and chemists have cautions that the distribution of what remains an unlicensed drug in the UK is a cause for concern and could lead to users injecting products of uncertain source.

Some professionals stated the popularity for the experimental drug could be connected to the increasing price of approved weight loss treatments such as Mounjaro.

Legal Status and Enforcement

Marketing retatrutide on social media or messaging apps is prohibited in the UK, as it is an unapproved drug that must not be promoted or distributed for personal consumption under the Human Medicines Regulations 2012.

Several influencers attempt to sidestep the regulations by calling to the drug as a “research chemical” or describing it as “not for human consumption”. Retatrutide is not a controlled drug, but advertising and supply can still breach pharmaceutical, marketing, and consumer laws, risking penalties, legal action or imprisonment.

Platform Response and Material Elimination

Based on the social media company, the platform has taken down violative material and banned associated hashtags and query recommendations. The organization stated it was committed to keeping the service safe and allocating resources in enhancing compliance measures.

Online Trading Activities

Research also discovered groups with up to nine thousand members marketing retatrutide using Telegram's integrated discovery tool, which operates like a public directory. Typing “retatrutide” immediately displays channels with thousands of members, populated with photos of slimming results, positive testimonials and detailed instructions for preparing or injecting at residence.

Within minutes of entering one community, a seller posted contact information, where most transactions take place. The seller provided an instruction manual and guaranteed shipping within two days. When questioned whether the product was genuine, one seller responded: “You can’t be sure.” Another shared a photo of a supposed laboratory certificate. None inquired about weight, medical conditions or past usage.

Product Details and Costs

Within these communities, messages show dark colored packages with postal service labels, stating to include fresh supplies. One message read: “It took eight of us to load them this morning.”

Customers can select between dry substance containers, prepared at home with purified liquid, or pre-filled pens typically sold at £160 for 20mg. When asked how much time a pen should be used, vendors give contradictory responses ranging from a few weeks to “depends on your body”.

Service Moderation and Safety Actions

A representative for the messaging service said it regularly moderated harmful material on its platform including material that promoted the “misuse of controlled medications”. The company noted that it eliminated “millions of pieces of harmful content each day”.

Medical Expert Cautions

“People are administering substances they cannot confirm. Although the science behind this drug is sound, these digital versions may not include what they claim,” stated a pharmacy expert, the director of pharmacy at Chemist4U.

A medical professional of an online medical service linked the increase in interest to current price rises for approved slimming drugs such as Mounjaro. “With costs rising, individuals are turning to social media. But fake treatments are extremely risky. You cannot know what’s contained or whether the conditions they were made in was clean,” she said.

Her staff has already encountered patients injured by self-injection from unconfirmed suppliers. “We recognize the disappointment, but purchasing from messaging apps or WhatsApp is taking chances with your health,” stated the doctor. “These materials could be contaminated or improperly measured.”

Manufacturer Position

A spokesperson from Eli Lilly stated retatrutide was in third stage clinical trials and had not been reviewed or approved by any regulatory agency anywhere in the world. “Therefore at this time no one can market [it] for personal consumption,” they explained, adding that any item “misleadingly claiming itself as a company experimental product not yet authorized … may expose users to possibly serious medical dangers”.